Display Settings:

Format

Send to:

Choose Destination
    Clin Oncol (R Coll Radiol). 2005 May;17(3):174-84.

    What's new in the management of cutaneous T-cell lymphoma?

    Source

    Southampton Oncology Centre, Southampton University NHS Trust, Southampton S016 6YD, UK.

    Abstract

    The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.

    PMID:
    15901002
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk